Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imsidolimab in EGFRi/MEKi-associated acneiform rash
NCT04697069Phase 2Terminated
- Sponsor
- Vanda Pharmaceuticals Inc.
- Start
- May 2021
- Primary completion
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of imsidolimab in acneiform eruption, sponsored by Vanda Pharmaceuticals Inc.. Started May 2021; status: terminated.
02
Drugs
imsidolimab
03
Conditions
acneiform eruption
Beyond the preview
Go deeper on NCT04697069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04697069.